Charles River Laboratories International
 
 
 
 
公司概覽
業務類別 Diagnostics & Research
業務概覽 Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
公司地址 251 Ballardvale Street, Wilmington, MA, USA, 01887
電話號碼 +1 781 222-6000
傳真號碼 --
公司網頁 https://www.criver.com
員工數量 19700
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Mr. Mark Mintz Corporate Executive Vice President and Chief Information Officer & Global Shared Services -- 18/02/2026
Ms. Birgit Girshick Chief Operating Officer and Director 美元 760.96K 09/01/2026
Mr. Joseph W. LaPlume Corporate Executive Vice President, Corporate Development and Strategy 美元 570.17K 18/02/2026
Ms. Shannon M. Parisotto Corporate Executive Vice President -- 18/02/2026
Mr. James C. Foster Chairman of the Board, President and Chief Executive Officer 美元 1.55M 09/01/2026
Mr. Michael Gunnar Knell Corporate Senior Vice President and Chief Accounting Officer 美元 448.12K 18/02/2026
Ms. Victoria L. Creamer Corporate Executive Vice President 美元 553.75K 18/02/2026
Mr. Glenn G. Coleman, C.P.A. Corporate Executive Vice President and Chief Financial Officer -- 18/02/2026
 
董事會成員
董事會 職務 更新日期
Mr. Steven K. Barg Independent Director 31/03/2026
Mr. Mark Joseph Enyedy Independent Director 31/03/2026
Mr. Paul W. Graves Independent Director 31/03/2026
Ms. Birgit Girshick Chief Operating Officer and Director 09/01/2026
Mr. George Llado, Sr Independent Director 31/03/2026
Ms. Reshema Kemps-Polanco Independent Director 31/03/2026
Mr. Abraham Ceesay Director 31/03/2026
Mr. James C. Foster Chairman of the Board, President and Chief Executive Officer 09/01/2026
Dr. Martin W. Mackay, PhD Independent Director 09/01/2026
Dr. Nancy C. Andrews, M.D.,PhD Independent Director 31/03/2026
Dr. Craig B. Thompson,M.D. Independent Director 31/03/2026
Ms. Virginia M. Wilson Independent Director 31/03/2026
 
所屬ETF (更新日期: 02/05/2026 02:48)
代號 名稱 佔比% 持有日期
AVSUAvantis Responsible US Equity ETF0.0004%29/04/2026
GSPYGotham Enhanced 500 ETF0.0004%29/04/2026
HCMTDirexion HCM Tactical EnhU.S.EqStratETF0.0004%29/04/2026
SPUUDirexion Daily S&P 500® Bull 2X ETF0.0003%29/04/2026
SQSSapient Quality Select ETF0.0003%17/04/2026
STXGStrive 1000 Growth ETF0.0003%29/04/2026
STXVStrive 1000 Value ETF0.0002%29/04/2026
GOFGuggenheim Strategic Opp Fund0.0002%30/11/2025
MMTMState Street® SPDR® S&P® 1500MomtTiltETF0.0002%29/04/2026
SPXNProShares S&P 500® ex-Financials0.0001%29/04/2026
SPXEProShares S&P 500® ex-Energy0.0001%29/04/2026
AAUAAlpha Architect US Equity 3 ETF0.0001%10/04/2026
ONEOStt Strt® SPDR® Russell 1000 Momt FocETF0.0001%29/04/2026
XOEFiShares S&P 500 ex S&P 100 ETF0.0001%29/04/2026
SPYHNEOS S&P 500 Hedged Equity Income ETF0.0001%29/04/2026
XYLGGlobal X S&P 500® Covered Call & Gr ETF0.0001%29/04/2026
XRMIGlobal X S&P 500® Risk Managed Inc ETF0.0001%29/04/2026
AVTMAvantis Total Equity Markets ETF0.0001%29/04/2026
PHDGInvesco S&P 500® Downside Hedged ETF0.0001%29/04/2026
REMCColumbia Research Enhanced Mid Cap ETF0.0001%29/04/2026
  1    2    3    4    5    6    7   8    9    10    11    12  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.